George Dimitrov: SII and Cancer – What Can This Marker Really Tell Us
George Dimitrov, Assistant Professor at Medical University of Sofia, MUS, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Diseases, adding:
“Our second cardio-oncology collaboration from University Hospital ‘Tsaritsa Yoanna–ISUL’, looking at the systemic immune–inflammation index (SII) in 330 patients with solid malignancies.
Interestingly, SII did not help distinguish patients with cancer-associated thrombosis (AUC 0.515), but higher SII was independently associated with recorded all-cause mortality (OR 1.31 per 1000-unit increase, p equals 0.016).
Perhaps SII is less useful as a thrombosis marker and more reflective of the overall inflammatory burden of cancer.
A nice example of how sometimes the most interesting finding is not the one you set out to find.”
Title: Systemic Immune–Inflammation Index, Thrombotic Status, and Mortality in Patients with Cancer: A Matched Cohort Study
Authors: Bozhidar Krastev, Natalia Spasova, Georgi Dimitrov, Elena Kinova, Assen Goudev
Stay updated with Hemostasis Today.
-
Sep 19, 2026, 18:03Manisha Madkaikar: Clinical, Hematological, and Molecular Features of Sickle β-Thalassemia
-
Sep 19, 2026, 17:24Jan Shawqi Goran: Understanding Beta Thalassemia Before Marriage Testing
-
Sep 19, 2026, 14:17Abdul Mannan: What Exactly Is a Platelet?
-
Sep 19, 2026, 13:39Keisuke Goda: Decoding Platelet Phenotypes in COVID-19 With Optofluidic Imaging
-
Sep 19, 2026, 13:30Targeted Thrombolysis Beyond tPA
-
Sep 19, 2026, 13:21Paul Armstrong: From Summer Studentship to Young Researcher
-
Sep 19, 2026, 13:06Rabiya Masood: Breaking the Cycle of Thalassemia Through Screening
-
Sep 19, 2026, 10:52Consuela A. Albright: The Critical Role of Black Blood Donors in Sickle Cell Treatment
-
Sep 19, 2026, 10:47Amber Yates: Inside Agios’ Partnership with the Sickle Cell Community